Metagenomi Therapeutics, Inc. filed a Current Report on Form 8-K dated September 21, 2026, to furnish an updated corporate presentation. The filing details the company's financial position as of the end of the second quarter of 2026 and provides an overview of its pipeline and technology.
According to the presentation, Metagenomi reported cash, cash equivalents, and available-for-sale marketable securities totaling $120.7 million at the end of Q2 2026. The company stated that this cash balance is anticipated to support its operations through the fourth quarter of 2027.
The presentation outlines the company's strategy as a differentiated in vivo gene editing firm focused on creating curative genetic medicines. The core of the pipeline is the lead program, MGX-001, which targets hemophilia A. The presentation describes MGX-001 as a potentially durable, one-time curative therapeutic designed to deliver Factor VIII (FVIII) protein.
Preclinical data presented in the filing indicates that MGX-001 achieved Factor VIII activity levels within the normal range in non-human primates. The data also suggests durability, with stable expression observed over approximately 19 months in cynomolgus monkeys. Additionally, the presentation notes that off-target evaluation confirmed a favorable safety profile, with no off-target edits identified in primary human hepatocytes at doses exceeding therapeutic levels.
Beyond hemophilia A, Metagenomi discussed plans to expand indications using its site-specific gene integration systems and partnered assets. The company is exploring opportunities in neuromuscular diseases, liver diseases such as alpha-1 antitrypsin deficiency and Wilson disease, and cardiometabolic indications.
The presentation emphasizes the company's proprietary technology suite, which includes over 20,000 distinct gene editing tools. These tools are designed to offer high specificity, precision, and the ability to perform multiplexed editing across a broad range of genetic mutations.
